Century Therapeutics : Corporate Overview March 2024

Corporate Overview

March 2024

Forward-looking statements

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as

"may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation

are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through

development activities, preclinical studies, and clinical trials; our reliance on

the maintenance on certain key collaborative relationships for the

manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatoryapproval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties inconnection with the development of our product candidates, including third parties conducting our future clinical trials as wellas third-party suppliers and

manufacturers; our ability to successfully commercialize our product

candidates and develop sales and marketingcapabilities, if our product

candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. Theseand other risks and

uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and

available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward- looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

2

Century Therapeutics: Building an industry-leading, next- generation allogeneic iPSC-derived cell therapy platform

LIMITLESS POTENTIAL…

PRECISION DESIGN…

ENDURING IMPACT…

Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturing

Progressing differentiated clinical programs based on Allo-EvasionTM technology in oncology and autoimmune and inflammatory diseases

Well-capitalized into 2026 to enable delivery on key milestones and clinical data

3

Overview of Foundational Platform Technologies

Versatility and unprecedented control: Century's next- generation allogeneic iPSC technology platform

• Allo-EvasionTM
• Homeostasis/ persistence
• Modulation of TME
• Safety switch

Engineered iPSC MCB

• Consistency

• Yield	iT cell

• Fitness: No exhaustion

Product design	Manufacturing
SINGLE CELL CLONING POST	DIFFERENTIATION
GENE EDITING AND
CHARACTERIZATION

iPSC

iNK cell

Iterative optimization of product functionality and manufacturability

5

Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates

Sequential selection steps

	Multiple gene edits
iPSC	(KO/KI)
bank	iSPC Precision Engineering

Engineered iPSC

Master Cell Bank

(MCB)

CRISPR-mediated HDR (MAD 7)

Advantages of Century's Platform

Precise CRISPR mediated homology directed repair reduces off-target integration

Stepwise and efficient gene editing avoids risky multiplex modification and structural variants

Quality control throughgeneration of homogenous MCB establishes genomic

product integrity

Manufacturing begins at the MCB, confirmed

to be free from genetic aberrations

6

Potential to drive durable responses with engineering to resist immune rejection

Allo-EvasionTM edits + repeat dosing = potential greater durability

With Allo-EvasionTM engineering

Without Allo-EvasionTM engineering

Next-wave of allogeneic cell therapies must solve for challenge of rejection

7

Allo-EvasionTM designed to overcome major pathways of host vs. graft rejection

CD8+

T Cell

β 2M KO	HLA-E KI	NK cell
(HLA-I)

HLA-G KI

CD4+	CIITA
T Cell	KO
	(HLA-II)

Core edits disarm host cells from eliminating therapy

1. Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells
2. Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells
3. Knock-inof HLA-E prevents killing by NK cells
4. Knock-inof HLA-G improves protection against killing by NK cells

Allo-EvasionTM

1.0

Allo-EvasionTM

3.0

8

Foundational investments in iPSC manufacturing

Established in-house manufacturing

• Accelerates learnings and enables faster product iteration
• 53,000 ft2 facility
• Designed to produce multiple immune cell types
• Two sites (FCDI GMP manufacturing, Century in-house manufacturing) provide optionality and maximizes flexibility

Developing fit-for-purpose products

• Increased process and product consistency
• Scalable platforms and optimized processes to maximize yield, reduce COGs, and meet demand
• Increases in cell fitness, as cells do not undergo excessive expansion cycles which often result in cell exhaustion
• Homogeneity of the manufacturing process produces a product candidate that can be readily characterized

9

Pipeline